A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

Eli Lilly and Company0 个研究点目标入组 1,000 人开始时间: 2022年4月27日最近更新: 2022年5月2日

适应症

试验速览

暂无简介。

•[1] Patient was between 6 and <18 years of age inclusive at the time of enrollment into Study LAHX or Study LAHV.
•[2] The patient has a minimum body weight of 15 kg.
•[3] The patient is able to swallow a tablet.
•[4] For patients taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to Visit 1.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 1000
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•[1] Patient is pregnant or breastfeeding.
•[2] Patient has, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
•[3] Patient has known allergies to lasmiditan, related compounds, or any components of the formulation.
•[4] In the opinion of the investigator or sponsor, patient is unsuitable for inclusion in the study.

发起方